Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

4 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

dbGaP phs001052 Multi-Dimensional ClinOmics for Precision Therapy - Eligibility

- 9/7/23 - 5 formularios, 1 itemgroup, 1 item, 1 idioma
Itemgroup: IG.elig
Principal Investigator: MeSH: Neoplasms,Sarcoma,Sarcoma, Ewing,Rhabdomyosarcoma,Wilms Tumor,Desmoplastic Small Round Cell Tumor,Carcinoma, Transitional Cell,Rhabdoid Tumor,Sarcoma, Synovial,Neuroblastoma,Neuroendocrine tumors https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001052 The Center for Cancer Research (CCR), of the intramural NCI undertook a multidimensional clinical genomics study of children and adolescent young adults with relapsed and refractory cancers who were enrolled on other therapeutic trials to determine the feasibility of a genome guided precision therapy protocol in these patients.

pht005466.v2.p1

1 itemgroup 2 items

pht005467.v2.p1

1 itemgroup 3 items

pht005468.v2.p1

1 itemgroup 3 items

pht005469.v2.p1

1 itemgroup 6 items

Eligibility DRKS00003795 NCT00643565 Sarcoma - Eligibility

- 15/4/14 - 1 formulario, 2 itemgroups, 9 items, 2 idiomas
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00643565

dbGaP phs000720 Genomic sequencing of Pediatric Rhabdomyosarcoma - Eligibility

- 29/1/25 - 5 formularios, 1 itemgroup, 1 item, 1 idioma
Itemgroup: IG.elig
Principal Investigator: Javed Khan, MD, National Institutes of Health, Bethesda, MD, USA MeSH: Rhabdomyosarcoma,Rhabdomyosarcoma, Alveolar,Rhabdomyosarcoma, Embryonal https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000720 Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood accounting for approximately 350 newly diagnosed cases yearly in the United States. With the development of multimodal chemotherapy regimens, relapse-free survival rates have improved to 70-80% in patients with localized disease albeit with significant toxicity. Unfortunately, despite aggressive treatment, patients with metastatic or recurrent disease continue to suffer from high mortality. Further characterization of the genetic events underlying this tumor type is critical for the development of more effective diagnostic, prognostic and therapeutic strategies. In a collaborative effort between the National Cancer Institute, the Children's Oncology Group, and the Broad Institute, we use a combination of whole-genome and whole-exome sequencing to characterize the landscape of somatic alterations in 147 tumor/normal pairs.

pht003878.v2.p1

1 itemgroup 3 items

pht003879.v4.p1

1 itemgroup 3 items

pht003881.v2.p1

1 itemgroup 7 items

pht003880.v2.p1

1 itemgroup 5 items

Eligibility NCT00642941 Sarcoma - Eligibility

- 9/12/13 - 1 formulario, 2 itemgroups, 8 items, 2 idiomas
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00642941

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial